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Summary An immunoperoxidase technique has been used to detect the in vivo binding of a 2-nitroimidazole
hypoxia marker in histochemical sections of a variety of excised canine tumours. The binding occurred 10-12
cell diameters away from tumour blood vessels, consistent with the expected location of hypoxic cells in tissues
in which oxygen concentration gradients are established by diffusion. Hypoxic fractions ranging from 4 to
13% have been estimated on the basis of morphometric analysis of multiple tumour sections. The binding of
the marker was restricted to the cytoplasm of the cells. The marker appeared in regions adjacent to necrosis
but also in regions free of necrosis. As in earlier autoradiography studies, binding was occasionally observed in
cells adjacent to tumour blood vessels. Generally, binding to normal tissues was not observed. However,
binding to smooth muscle cells surrounding arterioles in some sections of normal tissue and tumour tissue was
observed.
Viable, radioresistant hypoxic cells may compromise the
effectiveness of radiation treatment of tumours (Bush et al.,
1978; Thomlinson & Gray, 1955) but may also be targets for
selective cytotoxins (Kennedy, 1987). In either case, the
detection and measurement of tumour hypoxia would be of
prognostic value. A variety of methods have been used to
detect and measure the oxygenation status in cells and tissues
(for review see Franko, 1986). Methods which have been
investigated in clinical studies include oxygen electrodes
(Gatenby et al., 1988), intercapillary distance measurements
(Awwad et al., 1986) and bioreductive binding of marker
molecules (Urtasun et al., 1986).
The development of tumour hypoxia is usually attributed
to either diffusion limited (Franko & Sutherland, 1979; Kall-
man, 1972) or perfusion limited (Brown, 1979) oxygen
supply. An important aspect of diffusion limited oxygen dis-
tribution is that hypoxia develops over a few cell diameters
at the limit of the oxygen diffusion distance. A corollary is
that the method chosen for detecting diffusion limited or
'chronic' hypoxia in tumours should respond to oxygen
gradients on a cellular scale. One such method is the hypoxia
marker approach (Chapman, 1979; Chapman et al., 1981;
Franko, 1986).
Nitroheterocyclic compounds such as substituted 2-nitro-
imidazoles bind selectively to hypoxic cells in tissue culture
(Varghese & Whitmore, 1980) and it has been proposed that
this binding could be used to measure tumour hypoxia in vivo
(Chapman, 1979). The binding is a metabolic process involv-
ing endogenous nitroreductases which convert the nitro-
heterocyclic compounds to binding intermediates in an
oxygen dependent manner (Franko & Koch, 1984; Franko et
al., 1987). The binding occurs over the same oxygen concen-
tration range as that observed for the radiobiological oxygen
effect (Franko et al., 1987); it is localised to the hypoxic cells
in which the intermediates are produced (Franko et al.,
1984); and the intermediates incorporate the whole marker
molecule (Raleigh et al., 1985). The attractiveness of the
hypoxia marker approach has led to a variety of studies
which differ only in the label and detection technique used.
Autoradiographic detection of 3H or 14C labels (Chapman et
al., 1981; Franko, 1986), positron emission tomographic
visualisation of F-18 labels (Rasey et al., 1989), gamma-ray
scintigraphic detection of gamma emitting halogen labels
(Jette et al., 1983) and magnetic resonance spectroscopy of
F-19 labels (Raleigh et al., 1986; Maxwell et al., 1989) have
all been used.
Recently, a fluorescence immunohistochemical approach
was used to detect hypoxic cells in spheroids and in trans-
planted animal tumours (Raleigh et al., 1987). Antibodies
which recognise the marker molecule CCI-103F (Raleigh et
al., 1986) were used to locate hypoxic cells in histochemical
sections of tumour tissues. The immunohistochemical ap-
proach can be quantified (Miller et al., 1989) and has con-
siderable potential as a means of measuring tissue hypoxia.
We have now extended our earlier studies to hypoxia marker
detection in spontaneous canine tumours.
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Materials and methods
Marker synthesis and antibody production
The hypoxia marker, 1-(2-hydroxy-3-(1,1,1,3,3,3-hexafluoro-
isopropoxypropyl)-2-nitroimidazole (CCI-103F) and rabbit
polyclonal antibodies to protein-bound CCI-103F were pre-
pared and characterised as previously published (Raleigh et
al., 1986, 1987).
Spheroid culture and labelling
Spheroids of EMT6/Ed tumour cells were prepared and
exposed to 0.10 mM CCI-103F in an air-saturated medium
for 3 h as described previously (Raleigh et al., 1987). The
labelling procedure produced no detectable cytotoxicity to
cells in the spheroids. The spheroids were harvested, washed
several times with saline to remove unbound drug and fixed
by immersion in 95% ethanol at 4°C followed by routine
paraffin embedding. Histochemical sections (41m) of the
fixed spheroids tissue were prepared and processed through
graded concentrations of ethanol into phosphate-buffered
saline (PBS, pH 7.2) and labelled with a standard peroxidase-
antiperoxidase technique (Wordinger et al., 1987).
Canine tumour in vivo labelling andpharmacokinetics
Canine patients with spontaneously arising neoplasms were
selected from the Oncology Service at the Teaching Hospital
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of the North Carolina State University College of Veterinary
Medicine. A variety of tumours was investigated including
recurrent subcutaneous mast cell tumours, a subcutaneous
haemangiopericytoma, a subcutaneous neurofibroma, a cu-
taneous squamous cell carcinoma and a rectal adenocar-
cinoma. Complete blood counts and routine serum chemistry
studies were performed on each dog before, and 24 h after,
admission of CCI-103F.
CCI-103F at a concentration of 1.5 g I' in 0.9% saline
was administered to the dogs at a dose of 40 mg kg-'. The
drug was administered by way of the cephalic vein as a rapid
intravenous infusion of 5-10 min duration. Samples of
heparinised plasma were taken from the jugular vein at 15,
30 and 45 min and at 1, 2, 4, 8 and 24 h after the end of the
infusion. Plasma samples were centrifuged at 1,000 r.p.m. for
6 min, the serum drawn off and mixed with an equal volume
of 10% trichloroacetic acid, the precipitate spun down at
1,000 r.p.m. for 6 min and the supernatant analysed for CCI-
103F content by reversed phase, high performance liquid
chromatography (HPLC) on a 30 cm x 4 mm lBondapak
column (Waters Chrom. Div., Millipore Corp.) with 35%
aqueous acetonitrile as eluent flowing at 2.0 ml min-'. Detec-
tion of CCI-103F was at 320 nm by means of a Spectra
Physics model 8450 variable wavelength detector.
Immunohistochemistry ofcanine tumours
Tumours were excised 24 h after the administration of CCI-
103F. In the case of the rectal adenocarcinoma the tumour
was obtained at post-mortem examination. The 24 h time
was chosen in order to maximise the level of hypoxia marker
binding by prolonging the exposure of the tumours to cir-
culating CCI-103F while, at the same time, ensuring that
CCI-103F would be largely cleared from the circulation at
the time of analysis. No attempt was made in these studies to
follow the binding as a function of time after injection.
Samples of tissue from each tumour were promptly fixed and
processed into paraffin blocks according to standard techni-
ques. The excised tumour mass was cut transversely at I cm
intervals; the anterior faces of the resulting slabs were then
cut into I cm square by 3 mm thick samples for histological
processing. In the interest of determining the optimum proce-
dure for antigen preservation, several fixatives were investi-
gated including cold 95% ethanol; 10% neutral phosphate-
buffered formalin; formaldehyde, acetic acid, picric acid
(Bouin's solution) and buffered formaldehyde, glutaraldehyde
(Trump's fixative). In each case the fixed tissues were embed-
ded in paraffin.
Paraffin blocks from each neoplasm were sectioned at 4tim
and stained by either avidin-biotin complex or peroxi-
dase-antiperoxidase (PAP) methods. In the avidin-biotin
method, sections were hydrated and exposed to rabbit anti-
CCI-103F in PBS overnight at 4°C. Biotinylated goat anti-
rabbit antibody was then applied to the sections for 1 h at
37C followed by incubation with streptavidin for 20 min. In
the peroxidase-antiperoxidase method sections were pre-
pared and exposed to 0.3% hydrogen peroxide, followed by
goat non-immune serum and overnight incubation with rab-
bit anti-CCI-103F at 4°C. Peroxidase-conjugated goat anti-
rabbit IgG was then applied to the sections followed by goat
antiperoxidase IgG. The chromogen used to detect the
presence of peroxidase was 1% aminoethyl carbazole in
phosphate buffered saline.
Based on the premise that cellular immunoreactivity re-
flects the presence of hypoxic cells, hypoxic fractions in the
tumour tissues were measured by morphometric analysis as
follows. Ten histological sections were selected randomly
from each tumour. With a light microscope at 400 x magni-
fication, a 5 x 5 ocular grid was used to select cells for
counting after a modification of the method of Garcia et al.
(1986). In each section, five or more fields were counted in
the haematoxylin and eosin stained sections to attain a total
count of at least 500 cells. The numbers of labelled cells were
then counted in the same fields using immunoreactivity to the
PAP stain as the marker of hypoxic cells. An estimate of the
error in determining hypoxic fraction using this approach
was made by repeating the procedure three times with one
heavily labelled tumour and one lightly labelled tumour and
using the data to calculate the mean and standard deviation
of the three independent measurements.
Results
Spheroids
The distribution of peroxidase labelling in spheroids exposed
to CCI-103F in aerated culture medium (Figure 1) was
similar to that shown previously in autoradiographic and
fluorescence immunohistochemical studies with CCI-103F
confirming that the peroxidase labelling approach did not
alter the labelling pattern of hypoxic cells in the spheroid
model (Miller et al., 1989; Raleigh et al., 1987). In particular,
there is no labelling of either the outer, well-oxygenated or
the central, necrotic regions of the spheroid. The label was
visibly restricted to the cytoplasm of the cells which is a
feature not evident in the earlier autoradiographic and fluor-
escence immunohistochemical studies.
Canine pharmacokinetics
A peak concentration of CCI-103F was reached in the blood
within 30 min of injection. Only low concentrations of the
marker could be detected 24 h after its injection. The first
order pharmacokinetic plot in Figure 2 shows the plasma
concentrations of CCI-103F as a function of time after intra-
venous injection. Each point represents the mean and stan-
dard deviation of data derived from the nine dogs analysed
to date. Regression analysis was used to calculate a mean
plasma half-life of 7.9 h for CCI-103F. This compares with a
shorter plasma half-life of 3.7 h for i.v. administered
misonidazole (White et al., 1982) and 5.0 h for orally
administered misonidazole (Creasey & Thrall, 1982) in dogs.
A two-fold longer half-life for CCI-103F relative to
misonidazole has also been observed for mice. This was
attributed to the greater lipophilicity ofCCI-103F (Raleigh et
al., 1986). There were no major metabolites of CCI-103 F
detected at 320 nm in the HPLC chromatograms. In earlier
studies involving the detection of radioactive metabolites, a
seemingly prominent, polar metabolite appeared in the
plasma of mice injected with tritiated CCI-103F (Raleigh et
al., 1986). It is now known that the most abundant, tritium-
containing polar metabolite under these circumstances is
tritiated water which is formed in a minor pathway by the
metabolic release of tritium from the sidechain of the labelled
compounds (Franko et al., 1989). Blood count and routine
serum chemistry analyses of blood samples drawn from the
dogs injected with CCI-103F showed no significant abnor-
malities.
Figure 1 Immunoperoxidase labelling of hypoxic cells in an
EMT/6 spheroid incubated with CCI-103F in aerated medium.
The labelled hypoxic cells are adjacent to the necrotic centre
which is in the centre of the section. Spheroids which have not
been exposed to CCI-103F show no labelling when the antibody
to CCI-103F is applied to them (data not shown).TUMOUR HYPOXIA 927
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Figure 2 First order pharmacokinetic plot of the plasma concen-
trations of CCI-103F as a function of time after intravenous
injection. The data points are the mean plasma concentrations for
the nine dogs analysed to date. A plasma half-life for CCI-103F
of 7.9 h can be calculated from these data.
Tumourfixation andstaining
Various fixatives including cold 95% ethanol, 10% formalin,
Bouin's fixative and Trump's fixative were compared. In spite
of the generally favourable preservation reported for tissue
antigens with cold ethanol fixation, it was found that cold
95% ethanol provided no advantage over the more conven-
ient formalin-containing fixatives each of which provided
better tissue preservation and section adhesion than did
ethanol. Bouin's fixative produced a slightly higher non-
specific background staining than the other fixatives. In our
hands, the peroxidase-antiperoxidase method of tissue stain-
ing gave a better hypoxia marker detectability against back-
ground than the staining produced by the avidin-biotin
complex method.
Hypoxia marker detection
In general, the distribution of labelled cells in the tumours
was consistent with the expected location of hypoxic cells in
tissues for which oxygen concentration gradients are estab-
lished by diffusion (Franko & Sutherland, 1979; Kallman,
1972; Thomlinson & Gray, 1955). Labelled cells consistently
appeared at distances of 10-12 cell diameters (100-1501 m)
from blood vessels (Figures 3-6) independently of whether
necrosis was present. This labelling pattern was easily discer-
Figure 3 Immunoperioxidase labelled section of an excised
canine mast cell tumour following in vivo labelling with CCI-
103F. The cells binding CCI-103F appear at 10-12 cells dia-
meters away from the blood vessels which are identified by
arrows. Bar = 250Im.
Figure 4 Higher magnification of the immunoperoxidase labelled
tumour section from Figure 3. The labelling is over the cytoplasm
with little or no nuclear labelling. Bar = 50pm.
nible in the haemangiopericytoma, the neurofibroma and the
mast cell tumours which, in general, contained uniform
sheets of tumour cells penetrated at intervals by blood
vessels. The relatively sparsely labelled mast cell tumours
typically produced sections with isolated islands of labelled
cells (Figure 3) whereas the heavily labelled haemangio-
pericytoma produced many fields of intense labelling (Figure
5). The apparent difference in intensity of labelling between
these two tumour types is not due to differing development
conditions for the PAP staining but due to a difference in the
number of cells labelled.
Occasionally, labelling was observed adjacent to tumour
blood vessels (data not shown) which is similar to the results
ofearlier autoradiographic studies (Urtasun et al., 1986). The
overall labelling pattern was independent of location within
the tumour in the sense that samples taken from the margins
of the tumours contained proportions of hypoxic cells similar
to those taken from the centers of the same tumours. This is
similar to the results for EMT6 mouse tumours (Chapman et
al., 1981). The immunohistochemical technique revealed that
the labelling was discrete and restricted to the cytoplasm of
the labelled cells (Figures 4, 6 and 7).
The cells which bound the hypoxia marker in the rectal
adenocarcinoma were often nested in the midst of extensive
intercellular connective tissue (data not shown). In this case,
it was difficult to establish the clear spatial relationship
between hypoxia marker binding and landmark blood vessels
which was observed in the other tumours. An additional
feature of the complex tissue structure of the adenocar-
Figure 5 Immunoperoxidase labelled section of an excised
canine haemangiopericytoma following in vivo labelling with CCI-103F. Bar = 250ism.928 J.M. CLINE et al.
TableI Percentageofcellslabelledwithhypoxiamarkerinavarietyof
canine tumours
Tumour volume Percentage
Tumour type (ml) labelled
Mast cell tumour 66 4± 1.2
Mast cell tumour 20 3
Haemangiopericytoma 50 13±0.05
Squamous cell carcinoma 13 5
Fibrosarcoma 800 4
Neurofibroma 24 7
Rectal adenocarcinoma 4 9
Figure 6 Higher magnification of the immunoperoxidase labelled
tumour in Figure 5. Bar = 50ym.
Figure 7 Immunoperoxidase labelling of smooth muscle cells
surrounding an arteriole in a section of normal tissue. The label
is cytoplasmic and predominantly perinuclear. Neither vascular
endothelal nor surrounding tissue cells are labelled. Relatively
few of the arterioles in the sections possessed labelled smooth
muscle cells. Bar = 50 tLm.
cinoma was the presence of infiltrating host lymphocytes
which were often near labelled tumour cells but were not
themselves labelled. Bone marrow cells are known to be
labelled by the hypoxia markers under hypoxic conditions
(Allalunis et al., 1983) and it is unlikely that host lym-
phocytes in the adenocarcinoma which are derived from bone
marrow cells would be unlabelled because they lack the
necessary nitroreductases to effect binding of CCI-103F in an
hypoxic environment. An alternate possibility is that the
lymphocytes are highly mobile and either infiltrated the
tumour towards the end of the 24 h labelling period or, being
labelled in the early stages of exposure, had migrated out of
the tissue at the time of analysis. The resolution of these
possibilities is beyond the scope of the present investigation.
The complex nature of the adenocarcinoma sections did not
prevent an estimate of hypoxic fraction from being made
(Table I). However, in three mast cell tumours out of the
total of 10 tumours of all types that have been studied,
extensive infiltration of host cells or the presence of fibrosis
reduced the number of tumour cells in the fields to levels
which precluded analysis of hypoxic fraction.
Estimates of hypoxic fractions in the seven tumours which
could be analysed are presented in Table I. Mean and stan-
dard deviation determinations as described above were per-
formed on two of the tumours. The etimated errors, which
we believe to be representative for lightly, labelled tumours
(mast cell) and heavily labelled tumours (haemangioperi-
cytoma), are included in Table I. The remaining estimates of
hypoxic fraction are the results of determinations on a single
series of sections from each tumour. The hypoxic fractions
are not related to the size of the tumour. For example, the
largest tumour, the fibrosarcoma at 800 g, has the same
degree of labelling as the much smaller mast cell tumours.
Normal tissue cells which appeared in the tumour sections
generally were not labelled. One exception was the labelling
of smooth muscle cells surrounding some arterioles in the
sections (Figure 7). The cytoplasm of the myocytes was
intensely labelled with an indication of enhanced labelling
near the periphery of the nucleus. The labelling of the
arteriole smooth muscle cells has not previously been
reported. Earlier studies with rodents have indicated that
normal tissues such as liver and skin are labelled by the
hypoxia markers (Van Os-Corby et al., 1987; Franko et al.,
1989; Cobb et al., 1990) but no investigation of these tissues
was carried out on the canine patients.
Discussion
The distribution of the hypoxia marker in EMT6/Ed
spheroids as detected by peroxidase immunohistochemistry is
consistent with the expected location of hypoxic cells and is
in agreement with previous results with fluorescence immuno-
histochemistry and autoradiography (Miller et al., 1989;
Raleigh et al., 1987). In general, the spheroid system, with its
three-dimensional array of cells in which the oxygen gradient
profile is well-characterised, is a useful test system for an
hypoxic marker (Franko, 1986). Earlier autoradiographic
studies in which the binding of tritium-labelled CCI-103F
and the reference hypoxia marker, misonidazole, were com-
pared showed that CCI-103F was indistinguishable from
misonidazole in revealing oxygen profiles in EMT6 spheroids
(Raleigh et al., 1987). In those studies it appeared that
CCI-103F might bind to aerobic cells to a greater extent than
misonidazole. However, this conclusion was based on auto-
radiographic grain counts over aerobic cells where the
number of grains is the lowest and the counting the least
precise. There is no indication from the peroxidase results
(Figure 1) or from quantitative immunofluorescence studies
(Miller et al., 1989) that CCI-103F binds to a measurable
extent to the outer aerobic cells in the spheriod. It is impor-
tant at this stage of hypoxic marker development that a
marker such as CCI-103F behaves in a manner analogous to
that of misonidazole because of the extensive investigations
both in vitro and in vivo which have been used to establish
misonidazole as a marker of hypoxic cells (Franko et al.,
1987; Franko, 1986; Chapman et al., 1981). To a large
extent, the inferences drawn from the binding patterns of
CCI-103F in the sections of the spontaneous canine tumours
reported here rest on the experimentally supported premise
that misonidazole is a useful marker of in vivo tissue hypoxia
and that CCI-103F mimics misonidazole in this regard.
Labelled cells in the excised canine tumours were generally
observed to occur 10-12 cell diameters away from visible
blood vessels in the tumour sections (Figures 3-7). This
coincides with the expected diffusion distance of oxygen
under normal physiological conditions (Franko & Koch, 1984;
Franko & Sutherland, 1979; Kallman, 1972; Thomlinson &
Gray, 1955) and indicates an unremarkable rate of oxygen
consumption in the canine tumours relative to both rodentTUMOUR HYPOXIA 929
and human tumours studied to date. In addition, it is per-
haps interesting that labelled tumour cells appeared in the
absence of obvious necrosis. Necrosis has been an important
landmark in the identification of hypoxic regions in tumours
(Franko & Sutherland, 1979; Thomlinson & Gray, 1955) but
the marker approach clearly indicates that hypoxic cells can
exist in tumours in the absence of frank necrosis. It remains
uncertain whether necrosis-associated hypoxic cells are viable
and clonogenic and hence able to contribute to tumour
radioresistance. The same question remains for the labelled
cells in Figures 3-6 but there is no indication of severe
nutrient deprivation such as the presence picnotic or degen-
erate cells which are frequently observed in the regions of
frank necrosis.
The estimate of hypoxic fraction in the tumours by the
immunohistochemical approach appears to be feasible (Table
I). The procedure reproduces many of the observations of
earlier autoradiographic studies including the observation
that tumour size alone is not a useful predictor of the extent
of hypoxia (Urtasun et al., 1986). Compared to the auto-
radiographic approach, the immunohistochemical method is
less time consuming and eliminates the need for radioactively
labelled markers. It remains to be seen, however, whether
the estimates of hypoxic fraction obtained here by mor-
phometric analysis of randomly selected sections taken from
throughout the tumours can be reproduced from data
gathered by the more limited biopsy sampling expected in a
clinical setting.
It is important to point out that the present results provide
no information on the actual concentration of oxygen in the
tumour tissues. However, the oxygen dependence of binding
of misonidazole to hypoxic tissues has been shown to be
similar to the oxygen dependence of radiation-induced cell
killing (Franko et al., 1987) and it would appear from the
spheroid results that CCI-103F shows a similar dependence.
Whether this binding will be predictive of tumour radiation
response remains to be investigated.
In addition to the preceding considerations, the hypoxic
fractions reported here must be considered as minimum
values. Studies with transplantable rodent tumours (Hirst et
al., 1982) have shown that tumour cells migrate from
oxygenated to hypoxic regions at a rate of 1.1-2.2jm h- as
cells close to capillaries proliferate and hypoxic cells distant
to capillaries are displaced into adjacent necrotic regions.
While the mean potential doubling time for spontaneous
canine tumours (5.4 ± 2.9 days; range 2.3-16 days) (Owen &
Steel, 1969) is much greater than that for rodent tumours
(1-2 days) and the cell migration rate in the spontaneous
tumours might, therefore, be expected to be much lower, the
possibility that previously well-oxygenated cells had migrated
into the hypoxic regions by the end of the 24 h labelling
period cannot be completely ruled out. The effect would be
an apparent decrease in the hypoxic fraction because labelled
hypoxic cells lost to necrosis would not have been counted in
the morphometric analysis. The widespread occurrence of
labelled cells in the spontaneous tumours in the absence of
necrosis might have been interpreted to mean that cell migra-
tion processes were not occurring. However, the overall cell
loss factors for rodent and spontaneous canine tumours are
similar (Hirst et al., 1982; Owen & Steel, 1969) so that
mechanisms of cell loss other than cell migration into necro-
tic regions may exist.
Autoradiographic studies of human tumours with radio-
actively labelled misonidazole revealed that tumour cells
adjacent to blood vessels can be labelled even though these
cells would be expected to be well-oxygenated. Similar labell-
ing was occasionally observed in the canine tumours (data
not shown). In the human tumours, this labelling was attri-
buted to perfusion limited oxygen supply with intratumoral
pressure implicated as a possible cause of blood vessel col-
lapse during the labelling period (Urtasun et al., 1986). Such
labelling of the canine tumours indicates the generality of the
phenomenon and, at the same time, shows that the immuno-
histochemical technique produces results consistent with the
autoradiographic technique.
In both liver cells and parasites such as schistosomes,
approximately 75% of the bioreductive binding of nitro-
heterocyclic compounds is to proteins (Smith, 1984; Tracy et
al., 1983). Thiol groups on proteins are likely to be major
binding sites for the bioreductively activated nitroheterocyclic
compounds (Chacon et al., 1988; Raleigh & Koch, 1990;
Varghese, 1983). In the case of the canine tumours, the in
vivo binding of CCI-103F to tumour cells and to smooth
muscle cells occurs primarily in the cytoplasm (Figures 4, 6,
and 7). This is consistent with protein being the predominant
macromolecular binding moiety in these cases as well. Cyto-
plasmic ribonucleic acids can bind 2-nitroimidazoles with the
same efficiency as proteins (Smith, 1984). However, even
though the polyclonal antibodies to CCI-103F detect only
sidechain determinants (Raleigh et al., 1987) and could not,
therefore, distinguish between RNA and protein binding, the
protein abundance in cells is 14 times greater than that of
RNA (Giese, 1968) and it may be assumed that the bulk of
the cytoplasmic binding is to protein.
Smooth muscle cells surrounding arterioles in sections of
both normal and tumour tissues were observed to occasion-
ally bind the marker (Figure 7). It is unlikely that smooth
muscle cells in close proximity to the lumen of arterioles are
normally hypoxic. Arteriolar P02 is approximately 95 mmHg
and diffusion of oxygen from the lumen of arterioles occurs
readily (Popel et al., 1989). Venous P02 is approximately
40 mmHg and the intracellular P02 in nearby tissues has been
estimated to be in the range of 10-20mmHg (Guyton,
1979). A similar estimate of 10 mmHg for some normal tissue
cell P02 was made on the basis of the radiation response of a
variety of normal tissues (Hendry, 1979). While it is con-
ceivable that 2-nitroimidazole markers might compete with
oxygen for electrons at these low P02 (Franko et al., 1987;
Rauth et al., 1984) and produce the uniform labelling
observed, for example, in liver sections (Van Os-Corby et al.,
1987), the selective labelling of smooth muscle cells in the
midst of other, unlabelled cells near the arterioles argues for
a special effect.
Smooth muscle cells control the constriction of arterioles
in response to local signals such as Pco2 , P02 (Guyton,
1979) and endothelium-derived nitric oxide (Vanhoutte,
1988). It is perhaps not surprising, therefore, that smooth
muscle cells might differ from surrounding cells in their
response to redox active compounds such as CCI-103F. Not
all arteriole smooth muscle cells in the tissue sections were
labelled which would appear to rule out the possibility that
the difference in these cells is due to the presence of a type I
nitroreductase such as diaphorase which can reduced nitro-
aromatic compounds in an oxygen independent way (Brun-
mark et al., 1988; Bryant & McCalla, 1980). An alternative
explanation is that transient hypoxia occurs in the tissue
encompassing the arteriole but that smooth muscle cells bind
CCI-103F at a rate vastly greater than the surrounding
tumour or normal cells. Under these circumstances it is
possible that smooth muscle cells would be preferentially
labelled to a detectable level before normoxic conditions were
reestablished and bioreductive binding in the region was
halted. This possibility is presently under investigation.
The binding of hypoxia markers to normal and otherwise
well-oxygenated tissue is a potential limitation to their use in
determining tumour hypoxia. However, normal tissue bind-
ing poses a problem only when the tumour tissue is not
clearly distinguished from interfering normal tissue. For
example, the labelling of normal tissues detected by scintilla-
tion counting of tissue homogenates labelled with tritium-
labelled misonidazole (Franko et al., 1989) would not
interfere with an analysis of excised tumour tissue. Non-
invasive methods for measuring tumour hypoxia such as
PET, MRS and gamma-ray scintigraphy, which rely on inte-
grated signals to estimate hypoxic fraction, might be more
prone to uncertainty with respect to the non-specific binding
of hypoxia markers but suitable localisation techniques could
minimise this problem.
In conclusion, the immunohistochemical approach de-
scribed here shows promise as a technique for measuring930 J.M. CLINE et al.
tumour hypoxia. The approach may complement non-
invasive techniques such as PET, MRI and gamma-ray scinti-
graphy and be particularly useful at low levels of hypoxic
fraction where the non-invasive techniques are relatively insen-
sitive. The comparison of immunohistochemical data on
tumour hypoxia with other histological data such as cell type,
degree of differentiation and proliferative status measured, for
example, by 5-bromodeoxyuridine labelled S phase cells in the
same tissue sections could also be instructive with respect to
the development of predictive assays of radiation response.
The binding of CCI-103F to the tumour cells is extensive and
it may be possible that the cell surface binding is sufficient to
permit sorting of labelled and unlabelled tumour cells by flow
cytometry. Marker-directed immunotherapy of hypoxic cells
is also conceivable but would be useful only if the binding to
normal tissue could be selectively inhibited.
We thank Dr S. Poppema, Cross Cancer Institute, Edmonton, Alberta
forthe immunoperoxidase staining ofthe spheroid samples, F.Y. Shum
for technique assistance in the synthesis and chromatographic analysis
ofCCI-103F and Dr G.G. Miller, Cross Cancer Institute and Dr E.M.
Zeman, Radiation Oncology Department, University of North
Carolina at Chapel Hill, for helpful discussions. We also thank Sandra
Horton, Histology Laboratory, College ofVeterinary Medicine, North
Carolina State University for the sectioning and immunoperoxidase
staining ofthe canine tumour samples. We gratefully acknowledge the
Alberta Cancer Board Research Initiative Program (A.J.F. and J.A.R.)
and theNational Cancer Institute GrantCA50995 forfinancial support
of this work.
References
ALLALUNIS, M.J., CHAPMAN, J.D. & TURNER, A.R. (1983).
Identification of a hypoxic population of bone marrow cells. Int. J.
Radiat. Oncol. Biol. Phys., 9, 227.
AWWAD, H.K., EL NAGGAR, M., MOCKTAR, N. & BARSOUM, M.
(1986). Intercapillary distance measurement as an indicator of
hypoxia in carcinoma ofthe cervix uteri. Int. J. Radiat. Oncol. Biol.
Phys., 12, 1329.
BROWN, J.M. (1979). Evidence for acutely hypoxic cells in mouse
tumours, and a possible mechanism of reoxygenation. Br. J.
Cancer, 52, 650.
BRUNMARK, A., CADENAS, E., SEGURA-AQUILAR, J., LIND, C. &
ERNSTER, L. (1988). DT-Diaphorase-catalyzed two-electron reduc-
tion of various p-benzoquinone and 1,4-naphthoquinone epoxides.
Free Radical Biol. Med., 5, 133.
BRYANT, D.W. & McCALLA, D.R. (1980). Nitrofuran induced
mutagenesis and error prone repair in Escherichia coli. Chem-Biol
Interactions, 31, 151.
BUSH, R.S., JENKIN, R.D.T., ALLT, W.E.C. &4 others (1978). Definitive
evidence for hypoxic cells influencing cure in cancer therapy. Br. J.
Cancer, 37, suppl. III, 302.
CHACON, E., MORROW, C.J., LEON, A.A., BORN, J.L. & SMITH, B.R.
(1988). Regioselective formation of a misonidazole-glutathione
conjugate as a function ofpH during chemical reduction. Biochem.
Pharmacol., 37, 361.
CHAPMAN, J.D. (1979). Hypoxic sensitizers: implications for radiation
therapy. N. Engl. J. Med., 301, 1429.
CHAPMAN, J.D., FRANKO, A.J. & SHARPLIN, J. (1981). A marker for
hypoxic cells in tumours with potential clinical applicability. Br. J.
Cancer, 43, 546.
COBBS, L.M., HACKER, T. & NOLAN, J. (1990). NAD(P)H nitroblue
tetrazolium reductase levels in apparently normoxic tissues: a
histochemical study correlating enzyme activity with binding of
radiolabelled misonidazole. Br. J. Cancer, 61, 524.
CREASEY, W.A. & THRALL, D.E. (1982). Pharmacokinetic and
antitumour studies with the radiosensitizer misonidazole in dogs
with spontaneous fibrosarcomas. Am. J. Vet. Res., 43, 1015.
FRANKO, A.J. (1986). Misonidazole and other hypoxia markers:
metabolism and applications. Int. J. Radiat. Oncol. Biol. Phys., 12,
1195.
FRANKO, A.J. & KOCH, C.J. (1984). Binding of misonidazole to V79
spheroids and fragments ofDunning rat prostatic and human colon
carcinomas in vitro. Diffusion of oxygen and reactive metabolites.
Int. J. Radiat. Oncol. Biol. Phys., 10, 1333.
FRANKO, A.J., KOCH, C.J., GARRECHT, B.M., SHARPLIN, J. &
HUGHES, D. (1987). Oxygen dependence ofbindingofmisonidazole
to rodent and human tumours in vitro. Cancer Res., 47, 5367.
FRANKO, A.J., RALEIGH, J.A., SUTHERLAND, R.G. & SODERLIND,
K.J. (1989). Metabolic binding of misonidazole to mouse tissues.
Comparison between labels on the ring and side chain, and the
production of tritiated water. Biochem. Pharmacol., 38, 665.
FRANK. A.J. & SUTHERLAND, R.M. (1979). Oxygen diffusion distance
anddevelopment ofnecrosis in multicell spheroids. Radiat. Res., 79,
439.
GARCIA,C.F.,WEISS, L.M., LOWDER,J. &4others(1986). Quantitation
and estimation oflymphocyte subsets in tissue sections. Am. J. Clin.
Pathol., 87, 470.
GATENBY, R.A., KESSLER, H.B., ROSENBLUM, J.S. & 4 others (1988).
Oxygen distribution in squamous cell carcinoma metastases and its
relationship to outcome ofradiation therapy. Int. J. Radiat. Oncol.
Biol. Phys., 14, 831.
GIESE, A.C. (1968). Cell Physiology, 3rd edn. W.B. Saunders: Philadel-
phia.
GUYTON, A.C. (1979). Physiology ofthe Human Body. 5th edn. W.B.
Saunders: Philadelphia.
HENDRY, J.H. (1979). Quantification of the radiotherapeutic impor-
tance ofnaturally hypoxic normal tissues from collated experiments
with rodents using single doses. Int. J. Radiat. Oncol. Biol. Phys., 5,
971.
HIRST, D.G., DENEKAMP, J. & HOBSON, B. (1982). Proliferation of
endothelial and tumour cells in three mouse mammary carcinomas.
Cell Tissue Kinet., 15, 251.
JETTE, D.C., WIEBE, L.I. &CHAPMAN, J.D. (1983). Synthesis and in vivo
studies of the radiosensitizer 4-(Br-82)-bromomisonidazole. Int. J.
Nucl. Med. Biol., 10, 205.
KALLMAN, R.F. (1972). The phenomenon of reoxygenation and its
implications for fractionated radiotherapy. Radiology, 105, 135.
KENNEDY, K.A. (1987). Hypoxic cells as specific drug targets for
chemotherapy. Anti-Cancer Drug Design, 2, 181.
MAXWELL, R.J.,WORKMAN, P. &GRIFFTHS,J. (1989). Demonstration
oftumor selective retention offluorinated nitroimidazole probes by
F-19 magnetic resonance spectroscopy in vivo. Int. J. Radiat. Oncol.
Biol. Phys., 16, 925.
MILLER, G.G., BEST, M.W., FRANKO, A.J., KOCH, C.J. & RALEIGH, J.A.
(1989). Quantitation ofhypoxia in multicellular spheroids by video
image analysis. Int. J. Radiat. Oncol. Biol. Phys., 16, 949.
OWEN, L.N. & STEEL, G.G. (1969). The growth and cell population
kinetics ofspontaneous tumours in domesticanimals. Br. J. Cancer,
23, 493.
POPEL, A.S., PITMANN, R.N. & ELLSWORTH, M.L. (1989). Rate of
oxygen loss from arterioles is an order of magnitude higher than
expected. Am. J. Physiol., 256, H921.
RALEIGH,J.A., FRANKO, A.J.,KOCH, C.J. &BORN,J.A. (1985). Binding
ofmisonidazole to hypoxic cells in monolayer and spheroid culture.
Evidence that a sidechain label is bound as efficiently as a ring label.
Br. J. Cancer, 51, 229.
RALEIGH,J.A., FRANKO, A.J.,TREIBER, E.O., LUNT,J.A. &ALLEN, P.S.
(1986). Covalent binding of a fluorinated 2-nitroimidazole to
EMT/6 tumours in BALB/C mice. Detection by F-19 nuclear
magnetic resonance at 2.3 T. Int. J. Radiat. Oncol. Biol. Phys., 12,
1249.
RALEIGH, J.A. & KOCH, C.J. (1990). The importance of thiols in the
reductive bindingof2-nitroimidazoles tomacromolecules. Biochem.
Pharmacol. (in the press).
RALEIGH, J.A., MILLER, G.G., FRANKO, A.J., KOCH, C.J.,
FUCIARELLI, A.F.&KELLY, D.A. (1987). Fluorescence immunohis-
tochemical detection ofhypoxic cells in spheroids and tumours. Br.
J. Cancer, 56, 395.
RASEY,J.S., KOH, W.,GRIERSON,J.R., GRUNBAUM, Z. &KROHN, K.A.
(1989). Radiolabelled fluoromisonidazole as an imaging agent for
tumour hypoxia. Int. J. Radiat. Oncol. Biol. Phys., 17, 985.
RAUTH, A.M., McCLELLAND, R.A., MICHAELS, H.B. & BATTISTELLA,
R. (1984). The oxygen dependence of the reduction of nit-
roimidazoles inaradiolyticmodel system. Int.J. Radiat. Oncol. Biol.
Phys., 10, 1323.
SMITH, B.R. (1984). Hypoxia enhanced reduction and covalent binding
of 2-(H-3)-misonidazole in the perfused rat liver. Biochem. Phar-
macol., 33, 1379.
THOMLINSON, R.H. &GRAY, L.H. (1955). The histological structure of
some human lung cancers and the possible implications for
radiotherapy. Br. J. Cancer, 9, 539.
TRACY, J.W., CATTO, B.A. & WEBSTER, L.T. (1983). Reductive
metabolism ofniridazole byadult Schistosomamansoni. Correlation
with covalent drug binding to parasite macromolecules. Mol.
Pharmacol., 24, 291.TUMOUR HYPOXIA 931
URTASUN, R.C., KOCH, C.J., FRANKO, A.J., RALEIGH, J.A. & CHAP-
MAN, J.D. (1986). A novel technique for measuring human tissue
Po2 at the cellular level. Br. J. Cancer, 54, 453.
VANHOUTTE, P.M. (1988). The endothelium - modulator of vascular
smooth-muscle tone. N. Engl. J. Med., 25, 512.
VAN OS-CORBY, D.J., KOCH, C.J. & CHAPMAN, J.D. (1987). Is
misonidazole binding to mouse tissues a measure of cellular P02?
Biochem. Pharmacol., 36, 3487.
VARGHESE, A.J. (1983). Glutathione conjugates of misonidazole.
Biochem. Biophys. Res. Commun., 112, 1013.
VARGHESE, A.J. & WHITMORE, G.F. (1980). Binding to cellular mac-
romolecules as a possible mechanism for the cytotoxicity of
misonidazole. Cancer Res., 40, 2165.
WHITE, R., WORKMAN, P. & OWEN, L. (1982). The pharmacokinetics
in mice and dogs of nitroimidazole radiosensitizers and chemosen-
sitizers more lipophilic than misonidazole. Int. J. Radiat. Oncol.
Biol. Phys., 8, 473.
WORDINGER, R.J., MILLER, G.W. & NICODENUS, D.S. (1987). Manual
of Immunoperoxidase Techniques. ASCP Press: Chicago.